Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia ― A Post-Marketing Survey (J-POSSIBLE) ―
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety and Effectiveness of Alirocumab, a Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor, in Patients With Familial or Non-Familial Hypercholesterolemia ― A Post-Marketing Survey (J-POSSIBLE) ―
Authors
Keywords
-
Journal
CIRCULATION JOURNAL
Volume -, Issue -, Pages -
Publisher
Japanese Circulation Society
Online
2023-01-11
DOI
10.1253/circj.cj-22-0445
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Coronary lesion complexity in patients with heterozygous familial hypercholesterolemia hospitalized for acute myocardial infarction: data from the RICO survey
- (2021) Hermann Yao et al. Lipids in Health and Disease
- Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
- (2021) Gissette Reyes-Soffer et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Familial Hypercholesterolemia in Patients with Acute Coronary Syndrome: Genetic Insights from EXPLORE-J
- (2021) Mariko Harada-Shiba et al. Journal of Atherosclerosis and Thrombosis
- The Prevalence and Diagnostic Ratio of Familial Hypercholesterolemia (FH) and Proportion of Acute Coronary Syndrome in Japanese FH Patients in a Healthcare Record Database Study
- (2020) Tamio Teramoto et al. Cardiovascular Therapeutics
- Treatment Patterns and Lipid Profile in Patients with Familial Hypercholesterolemia in Japan
- (2018) Tamio Teramoto et al. Journal of Atherosclerosis and Thrombosis
- Prevalence of familial hypercholesterolemia in patients with acute coronary syndrome in Japan: Results of the EXPLORE-J study
- (2018) Mariko Harada-Shiba et al. ATHEROSCLEROSIS
- Application of the Japanese Guidelines for the Diagnosis of Familial Hypercholesterolemia in General Practice: It is to be Validated in International Harmonization
- (2018) Nobukiyo Tanaka et al. Journal of Atherosclerosis and Thrombosis
- Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON
- (2018) Tamio Teramoto et al. Journal of Cardiology
- Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
- (2018) Gregory G. Schwartz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lipid Lowering Therapy and Circulating PCSK9 Concentration
- (2017) Tsuyoshi Nozue Journal of Atherosclerosis and Thrombosis
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
- (2017) Marc S. Sabatine et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Alirocumab in Japanese Patients With Heterozygous Familial Hypercholesterolemia or at High Cardiovascular Risk With Hypercholesterolemia Not Adequately Controlled With Statins – ODYSSEY JAPAN Randomized Controlled Trial –
- (2016) Tamio Teramoto et al. CIRCULATION JOURNAL
- Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
- (2015) Jennifer G. Robinson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Familial Hypercholesterolemia: An Under-recognized but Significant Concern in Cardiology Practice
- (2013) JoAnne M. Foody CLINICAL CARDIOLOGY
- Guidelines for the Management of Familial Hypercholesterolemia
- (2012) Mariko Harada-Shiba et al. Journal of Atherosclerosis and Thrombosis
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started